PMID- 34191191 OWN - NLM STAT- MEDLINE DCOM- 20210921 LR - 20210921 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 26 IP - 10 DP - 2021 Oct TI - Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. PG - 1947-1954 LID - 10.1007/s10147-021-01979-9 [doi] AB - BACKGROUND: The aims of this study were to investigate prognosis and validate prognostic models [Memorial Sloan-Kettering Cancer Center (MSKCC), International Metastatic Renal Cell Carcinoma Data Consortium (IMDC), and Japanese metastatic renal cancer (JMRC) models] in the targeted therapy era in Japanese patients with metastatic renal cell carcinoma. METHODS: We retrospectively analyzed 692 patients who were diagnosed with mRCC from January 2008 to August 2018 in the Michinoku Japan Urological Cancer Study Group database. Nivolumab as sequential therapy was widely used. Other immune checkpoint inhibitors were excluded from this study. RESULTS: The median overall survival (95% confident interval) in all, MSKCC favorable, intermediate, and poor risk patients was 41.0 months (33.9-46.8), not reached (63.5 to not estimable), 46.8 months (37.1-52.9), and 10.4 months (8.9-14.4), respectively. The median overall survival (95% confident interval) in IMDC favorable, intermediate, and poor risk patients was not reached (61.6 to not estimable), 47.4 months (41.4-56.5), and 11.5 (9.9-16.3), respectively. The c-index of the MSKCC, IMDC, and JMRC models calculated at mRCC diagnosis was 0.680, 0.689, and 0.700, respectively. No statistical differences were found in the c-index among the models. CONCLUSION: While the real-world overall survival in Japanese patients with mRCC in the targeted therapy era improved compared to that previously reported in the cytokine era, there was no clear difference in the survival of poor risk patients between these eras. There were no differences in the superiority among the models. CI - (c) 2021. Japan Society of Clinical Oncology. FAU - Naito, Sei AU - Naito S AUID- ORCID: 0000-0002-6104-4344 AD - Department of Urology, Yamagata University Faculty of Medicine, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan. seinaitoh@med.id.yamagta-u.ac.jp. FAU - Kato, Tomoyuki AU - Kato T AD - Department of Urology, Yamagata University Faculty of Medicine, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan. FAU - Numakura, Kazuyuki AU - Numakura K AD - Department of Urology, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 0368562, Japan. FAU - Koguchi, Tomoyuki AU - Koguchi T AD - Department of Urology, Fukushima Medical University School of Medicine, 1 hikarigaoka, Fukushima, 960-1295, Japan. FAU - Kandori, Shuya AU - Kandori S AD - Department of Urology, University of Tsukuba Graduate School of Medicine, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan. FAU - Kawasaki, Yoshihide AU - Kawasaki Y AD - Department of Urology, Tohoku University School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. FAU - Adachi, Hisanobu AU - Adachi H AD - Department of Urology, Miyagi Cancer Center, 47-1, Nodayama, Shiote, Medeshima, Natori, Miyagi, 981-1293, Japan. FAU - Kato, Renpei AU - Kato R AD - Department of Urology, Iwate Medical University School of Medicine, Yahaba 2-1-1, Shiwa, Iwate, 028-3695, Japan. FAU - Narita, Shintaro AU - Narita S AD - Department of Urology, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 0368562, Japan. FAU - Ogawa, Soichiro AU - Ogawa S AD - Department of Urology, Fukushima Medical University School of Medicine, 1 hikarigaoka, Fukushima, 960-1295, Japan. FAU - Kawamura, Sadafumi AU - Kawamura S AD - Department of Urology, Miyagi Cancer Center, 47-1, Nodayama, Shiote, Medeshima, Natori, Miyagi, 981-1293, Japan. FAU - Obara, Wataru AU - Obara W AD - Department of Urology, Iwate Medical University School of Medicine, Yahaba 2-1-1, Shiwa, Iwate, 028-3695, Japan. FAU - Ito, Akihiro AU - Ito A AD - Department of Urology, Tohoku University School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, University of Tsukuba Graduate School of Medicine, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan. FAU - Kojima, Yoshiyuki AU - Kojima Y AD - Department of Urology, Fukushima Medical University School of Medicine, 1 hikarigaoka, Fukushima, 960-1295, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 0368562, Japan. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan. FAU - Tsuchiya, Norihiko AU - Tsuchiya N AD - Department of Urology, Yamagata University Faculty of Medicine, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan. LA - eng PT - Journal Article DEP - 20210630 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 SB - IM MH - *Carcinoma, Renal Cell/drug therapy MH - Humans MH - Japan MH - *Kidney Neoplasms/drug therapy MH - Molecular Targeted Therapy MH - Prognosis MH - Retrospective Studies OTO - NOTNLM OT - Metastatic renal cell carcinoma OT - Overall survival OT - Prognosis OT - Prognostic model OT - Targeted therapy EDAT- 2021/07/01 06:00 MHDA- 2021/09/22 06:00 CRDT- 2021/06/30 12:35 PHST- 2021/05/26 00:00 [received] PHST- 2021/06/25 00:00 [accepted] PHST- 2021/07/01 06:00 [pubmed] PHST- 2021/09/22 06:00 [medline] PHST- 2021/06/30 12:35 [entrez] AID - 10.1007/s10147-021-01979-9 [pii] AID - 10.1007/s10147-021-01979-9 [doi] PST - ppublish SO - Int J Clin Oncol. 2021 Oct;26(10):1947-1954. doi: 10.1007/s10147-021-01979-9. Epub 2021 Jun 30.